-
1.发明公开Cysteine-depleted muteins of interferon-beta, their preparation, formulations containing them, and structural genes, vectors and organisms, and their production, suitable for use in the preparation of said muteins 失效干扰素β，它们的制备方法，含有这种突变蛋白和结构基因，载体和合适的用于生产使用生物组合物的半胱氨酸突变蛋白贫化所述的突变蛋白和它们的制备。
公开(公告)号：EP0218825A1
公开(公告)日：1987-04-22
申请号：EP86110595.5
申请日：1983-10-13
申请人： CETUS CORPORATION
发明人： Mark, David F. , Lin, Leo S. , Yu Lu, Shi-Da
CPC分类号： C07K14/55 , A61K38/00 , C07K14/565 , C12N15/102 , Y10S530/809 , Y10S930/141 , Y10S930/142
摘要： The invention provides muteins of the biologically active proteins of IFN-ß in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect intramolecular disulfide bridge formation. These muteins may be made via bacterial expression of mutant genes that encode the muteins and have been synthesized from the genes for the parent proteins by oligonucleotide-directed mutagenesis.
摘要翻译： 本发明提供IFN-β的生物活性蛋白，其中半胱氨酸残基没有是必不可少的生物活性已被删除或用其他氨基酸替换，以消除分子间交联或不正确的分子内二硫键的形成部位突变。 这些突变蛋白可通过突变体的基因的细菌表达制成并编码突变蛋白，并从基因通过寡核苷酸定向诱变的亲本蛋白质havebeen合成。
-
2.发明授权Cysteine-depleted muteins of interferon-beta, their preparation, formulations containing them, and structural genes, vectors and organisms, and their production, suitable for use in the preparation of said muteins 失效干扰素的CYSTEINE-DEPLETED MUTEIN，它们的制剂，含有它们的制剂以及结构基因，载体和有机物及其生产，适用于制备合适的MUTEINS
公开(公告)号：EP0218825B1
公开(公告)日：1989-09-20
申请号：EP86110595.5
申请日：1983-10-13
申请人： CETUS CORPORATION
发明人： Mark, David F. , Lin, Leo S. , Yu Lu, Shi-Da
CPC分类号： C07K14/55 , A61K38/00 , C07K14/565 , C12N15/102 , Y10S530/809 , Y10S930/141 , Y10S930/142
-
3.发明授权Pharmaceutical and veterinary preparations of cystein-125-depleted muteins of Interleukin-2 and their production 失效白介素-22的CYSTEIN-125-去皮质的药物和兽药的制备及其生产
公开(公告)号：EP0109748B1
公开(公告)日：1988-04-13
申请号：EP83306221.9
申请日：1983-10-13
申请人： CETUS CORPORATION
发明人： Mark, David F. , Lin, Leo S. , Yu Lu, Shi-Da
CPC分类号： C07K14/55 , A61K38/00 , C07K14/565 , C12N15/102 , Y10S530/809 , Y10S930/141 , Y10S930/142
-
4.发明公开Pharmaceutical and veterinary preparations of cystein-125-depleted muteins of Interleukin-2 and their production 失效药物和白细胞介素-2的兽医产品，已经在半胱氨酸125被替换为（突变蛋白），以及它们的制备。
公开(公告)号：EP0109748A1
公开(公告)日：1984-05-30
申请号：EP83306221.9
申请日：1983-10-13
申请人： CETUS CORPORATION
发明人： Mark, David F. , Lin, Leo S. , Yu Lu, Shi-Da
CPC分类号： C07K14/55 , A61K38/00 , C07K14/565 , C12N15/102 , Y10S530/809 , Y10S930/141 , Y10S930/142
摘要： The invention provides muteins of biologically active proteins such as IFN-B and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect intramolecular disulfide bridge formation. These muteins may be made via bacterial expression of mutant genes that encode the muteins and have been synthesized from the genes for the parent proteins by oligonucleotide-directed mutagenesis.
摘要翻译： 本发明提供了生物活性蛋白的突变蛋白：例如IFN-β和IL-2，其中半胱氨酸残基确实不是已被删除或用其它氨基酸取代，以消除分子间交联的或不正确的分子内二硫键形成位点至关重要的生物活性。 这些突变蛋白可通过突变体的基因的细菌表达制成并编码突变蛋白，并从基因通过寡核苷酸定向诱变的亲本蛋白质havebeen合成。
-
-
-
搜索结果
4 条记录 (耗时 0.008 秒)
